NovoCure's Return On Capital Employed Overview
Portfolio Pulse from Benzinga Insights
NovoCure (NASDAQ:NVCR) reported Q1 sales of $122.18 million and a loss of $53.06 million, with a return on capital employed (ROCE) of -0.12%. The negative ROCE suggests that management may not be effectively allocating their capital.
May 18, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NovoCure reported Q1 sales of $122.18 million and a loss of $53.06 million, with a negative ROCE of -0.12%, suggesting potential inefficiency in capital allocation.
NovoCure's negative ROCE of -0.12% in Q1 indicates that the company may not be effectively allocating its capital, which could negatively impact its stock price in the short term. Additionally, the company's earnings decreased by 42.24%, resulting in a loss of $53.06 million, which could further contribute to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100